CARBIOS produces first PET-bottles from 100% recycled plastic waste using Company’s breakthrough technology
CARBIOS (Paris:ALCRB) (Euronext Growth Paris: ALCRB), a company pioneering new, bioindustrial solutions to reinvent the lifecycle of plastic and textile polymers, today announced it has successfully produced the first PET-bottles made with 100% Purified Terephthalic Acid (rPTA), through the enzymatic biorecycling of plastic waste. This major milestone is a world-first and confirms the potential of the company’s technology to engage the whole industry in a responsible transition towards a circular economy.
Alain Marty, Chief Scientific Officer at CARBIOS, comments, “We have successfully developed the first biological process with which all kinds of PET plastic waste can be broken down into its original components and reused to produce virgin plastic products for applications such as PET-bottles. This new step shows the strong potential of CARBIOS’ enzymatic technology and provides a breakthrough solution to help solve society’s growing waste problem.”
Previously, CARBIOS demonstrated that its proprietary biorecycling technology, based on the use of bioengineered enzymes, had the ability to turn PET plastic waste back into its original components at a rate of 97% in only 16 hours. It had also demonstrated that virgin PET can be made with 100% rPTA via its proprietary biorecycling process, which uses all kinds of post-consumer PET plastic bottles (clear, colored, opaque, complex). By demonstrating today that 100% rPTA can be used to produce
PET-bottles that match brand and customer requirements, this technology proves to be a potential game-changer in the transition towards a circular economy that will benefit the environment and future generations.
PET is the most common polyester on the market. It is used to produce plastic packaging, textile fibers, and nearly 500 billion units of plastic bottles each year1. It is a market expected to grow 4.8% annually, from 2017 to 20252. By decoupling the production of new plastic bottles from petrochemical feedstock3 and making waste collection economically more viable, CARBIOS’ technology offers a sustainable and efficient solution to change the way we produce some of the most commonly used plastic products and meet the needs of brand-owners and consumers.
1 Source: Citi GPS - Global Perspectives & Solutions –
Rethinking Single-Use Plastics (August 2018)
2 Source: https://www.recycling-magazine.com/2019/01/24/market-study-sees-lots-of-potential-for-recycled-plastic/
3 See interesting reference: How much oil is used to make plastic? https://www.eia.gov/tools/faqs/faq.php?id=34&t=6
Jean-Claude Lumaret, CEO of CARBIOS, adds, “The plastics industry faces fundamental challenges related to sustainability. Our technology, based on a circular model, reuses resources rather than consuming them. This new milestone takes us one step closer to bringing our technology to the market. With the construction of our demonstration plant to start later this year, we’re aiming to engage the whole plastics industry in a transition towards a circular economy and take a leadership role as a global license provider for the biorecycling of PET plastics and fibers.”
Follow the link to discover more in video: Here
CARBIOS is a green chemistry company whose innovations provide solutions to the environmental and sustainable development issues manufacturers currently face. Since its founding in 2011, the company has developed two industrial-scale biological processes for the biological breakdown and recycling of polymers. These unique innovations help optimise the performance and life cycle of plastics and textiles by capitalizing on the properties of specially selected enzymes. CARBIOS’s economic growth model is based on the industrial roll-out and sale of its products, enzymes, technologies and biological processes through direct licence agreements or joint ventures, to major players in the fields to whom they would most benefit. To that end, CARBIOS founded the joint venture CARBIOLICE in 2016, in partnership with Limagrain Céréales Ingrédients and the SPI fund, run by Bpifrance. This company, in which CARBIOS holds a controlling share, will market the first technology licensed by CARBIOS by producing enzyme pellets used in the production of biodegradable and bio-sourced plastics. Since its founding, CARBIOS has been backed by Truffle Capital, a European investment capital player. CARBIOS qualifies as an “Innovative Company” according to Bpifrance, which makes the company’s shares eligible for inclusion in innovation-focused mutual funds (FCPIs). For more information, please visit: www.carbios.fr
CARBIOS is also eligible for inclusion in SME share savings accounts (PEA-PMEs).
This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country.
Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail.
+33 (0)4 73 86 51 76
Media Relations (Europe)
+33 (0)1 44 54 36 66
Media Relations (U.S.)
Kate L. Barrette
+1 212 223 0561
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development21.3.2019 13:44:00 CET | Pressemelding
Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate to take forward for manufacture. The new Developability Service reduces the time, risk and cost required to take multiple lead candidates through cell line development and manufacturing. Biologics have potential liabilities for safety, functionality, stability and scalability and when these issues are identified early alternate leads can be selected, liabilities engineered out or measures can be taken to mitigate risk. The Developability Service also enables the selection of drug candidates most aligned with the target product profile by evaluating a range of functionality and specificity readouts. The s
XPRIZE Identifies 10 Future Breakthroughs Required to Protect Our Forests21.3.2019 13:27:00 CET | Pressemelding
Today, on the United Nations’ International Day of Forests, XPRIZE is releasing the Future of Forests Impact Roadmap, created in partnership with Kimberly-Clark Corporation. The digital report and its interactive website, based on future foresight techniques, illustrate the breakthroughs required for a healthier forest ecosystem, which might be the basis of future XPRIZE competitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005409/en/ Across the world, forests provide food security and shelter, protect biodiversity and house indigenous populations. While forests cover more than 30 percent of the Earth’s surface, more than 32 million acres of forests are lost due to human activity every year, with research showing that continued mass deforestation and degradation is accelerating climate change. XPRIZE designs and operates global competitions to incentivize the development of technological breakthroughs that accel
Mark Thorne Joins BCW as Global Chief Financial Officer and Chief Operating Officer21.3.2019 13:17:00 CET | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, announced today that Mark Thorne has been appointed Global Chief Financial Officer and Chief Operating Officer, effective immediately. Thorne will be a strategic partner to BCW Global CEO Donna Imperato in transforming the agency’s financial model to better reflect its wide range of services and offerings. He is based in New York and replaces Pat Przybyski, formerly Global Chief Financial Officer. “Mark is well known for his strong business acumen, deep operational experience and high-level strategic thinking,” said Imperato. “I have known Mark for many years and am thrilled to now call him my partner. He is the right leader to help BCW execute our strategies and grow exponentially.” Thorne spent the past 20 plus years with Hill+Knowlton Strategies in a range of leadership roles, most recently serving as Global Chief Financial Officer and Global Chief Operating Officer. Prior to that, Thorne was Executive Vice President
Imago BioSciences Announces $40 Million Series B Financing Led by Omega Funds21.3.2019 13:09:00 CET | Pressemelding
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading international investment firm that creates and invests in life sciences companies. Other investors participating in the round include existing investors Frazier Healthcare Partners, Amgen Ventures, and MRL Ventures Fund as well as HighLight Capital, Pharmaron and Greenspring Associates. Dr. Dina Chaya from Omega Funds will join the board of directors and Dennis Henner will remain Chairman of the Board, representing his fund. “Imago BioSciences is extremely gratified with the interest and support of the investment community; we are particularly pleased with the composition of this new investment syndicate,” said Hugh Young Rienhoff, Jr. M.D., CEO at Imago BioSciences. “These funds will enable Imago to advance our programs through the completion of Phase 2b studies.” “We are excited to work wi
Workiva Wins DevOps Excellence Award in London21.3.2019 13:03:00 CET | Pressemelding
Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, today announced that its Wdesk platform was named the Best Software-Defined Product, last night at Computing's DevOps Excellence Awards dinner. The Computing DevOps Excellence Awards recognize outstanding achievement from organisations, personalities and solutions operating within the DevOps industry. Winners were selected on their superior functionality, level of ability to modernize business processes, positive customer feedback and a strong return on investment. “We are proud to win this prestigious award,” said Marty Vanderploeg, CEO of Workiva. “As the global leader in connected reporting, XBRL and Inline XBRL, our Wdesk platform helps customers all over the world consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders.” XBRL (eXtensible Business Reporting
Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate21.3.2019 11:30:00 CET | Pressemelding
Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in Barcelona, Spain, highlighting the effectiveness of the UroLift® System, a minimally invasive treatment, usually performed in-office that provides rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH).1,2 BPH, also known as enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.3 BPH affects over 40 million men in the United States alone.4 If left untreated, the condition can worsen over time and cause permanent bladder damage.5 A presentation entitled Pulling The Foley: Can the Prostatic Urethral Lift be used in men with catheter-dependent urinary retention? was presented by Thomas Mueller, M.D., urologist of New Jersey Urology (Voorhees, N.J.). The study highlighted real-world retrospective d